US Dry Age-Related Macular Degeneration (AMD) Market Research Report By Stage (Early Age-Related Macular Degeneration, Intermediate Age-Related Macular Degeneration, Late Age-Related Macular Degeneration), By Age Group (Above 75 years, Above 60 years, Above 40 years), By Diagnosis and Treatment (Treatment, Diagnosis), By Route of Administration (Oral, Injectables) and By End Users (Hospitals Clinics, Diagnostic Centers, Academic Research Institutes)-Forecast to 2035

US Dry Age-Related Macular Degeneration (AMD) Market Overview

The US Dry Age-Related Macular Degeneration (AMD) Market Industry is expected to grow from 1.2 (USD Billion) in 2024 to 2.5 (USD Billion) by 2035. The US Dry Age-Related Macular Degeneration (AMD) Market CAGR (growth rate) is expected to be around 6.9% during the forecast period (2025 - 2035).

Key US Dry Age-Related Macular Degeneration (AMD) Market Trends Highlighted

The US Dry Age-Related Macular Degeneration (AMD) Market is experiencing noteworthy trends shaped by a combination of demographic shifts and healthcare advancements. The aging population in the US is a significant driver, as individuals aged 65 and older are at a higher risk for developing AMD. This demographic change is becoming evident, with millions of Americans affected, prompting an increased focus on awareness and prevention. The push for early diagnosis and management of AMD is growing as healthcare providers emphasize the importance of regular eye exams and screening, which aligns with national health initiatives aimed at improving eye health among older adults.

Improvements in technologies and treatment options are improving the market economy of the US. New and emerging innovative therapies like nutritional supplements and possible outcome-shifting gene therapies are offering better hope in disease management. The mere fact that diverse biotech firms are trying to devise methods to mitigate the advance of dry AMD portrays positive research and development activity. Also, there is a movement towards the use of digital health technologies, including mobile applications and telehealth, that enable patients to be educated and monitored remotely, making it convenient for them to access care. There is also a developing trend of collaboration among various actors in the healthcare system, such as researchers, organizations, and ophthalmologists towards addressing the problem of dry AMD.

Public awareness campaigns and community programs focused on eye health are on the rise, aiming to educate the population about risk factors and prevention strategies. This comprehensive approach signals notable progress in addressing dry AMD and reflects a commitment within the US to improve patient outcomes and quality of life.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

US Dry Age-Related Macular Degeneration (AMD) Market Drivers

Increasing Aging Population

The aging population in the US is one of the most significant drivers of growth in the US Dry Age-Related Macular Degeneration (AMD) Market industry. According to the US Census Bureau, by 2030, nearly 1 in 5 Americans will be of retirement age, leading to a higher prevalence of age-related health issues, including AMD. As the likelihood of developing AMD increases with age, this demographic shift directly impacts market growth. The National Eye Institute also anticipates a significant rise in AMD cases, projecting that by 2050, over 5 million Americans will be diagnosed with some form of AMD.

This trend emphasizes the necessity for targeted therapeutic options and enhances the revenue potential within the US Dry Age-Related Macular Degeneration (AMD) Market industry as healthcare providers and pharmaceutical companies develop products to address this growing need.

Advances in Treatment Options

Technological advancements in the treatment of AMD are driving market growth within the US Dry Age-Related Macular Degeneration (AMD) Market industry. Ongoing research and clinical trials conducted by esteemed institutions, such as the National Institutes of Health (NIH), are exploring novel therapies, including gene therapy and regenerative medicine, which are showing promising results in combatting AMD. The emphasis on innovative treatment leads to increased investment from both the public and private sectors, driving market expansion.

A reported investment of over $500 million in AMD research from various stakeholders, including pharmaceutical companies and non-profits, showcases a strong commitment to finding effective solutions for AMD, which can significantly enhance patient outcomes.

Growing Public Awareness and Screening Initiatives

Public awareness campaigns and screening initiatives significantly impact the US Dry Age-Related Macular Degeneration (AMD) Market industry's growth. Organizations such as the American Academy of Ophthalmology are actively promoting programs aimed at educating the public about the risks and symptoms associated with AMD. Enhanced awareness leads to earlier diagnosis and increased demand for treatment solutions. A CDC report highlighted that early detection through screenings can reduce the risk of blindness by over 50%, prompting older adults to seek preventive measures.

As more individuals become conscious of AMD, the demand for diagnostic and therapeutic options in the US Dry Age-Related Macular Degeneration (AMD) Market industry is expected to rise markedly in the coming years.

US Dry Age-Related Macular Degeneration (AMD) Market Segment Insights

Dry Age-Related Macular Degeneration (AMD) Market Stage Insights

The US Dry Age-Related Macular Degeneration (AMD) Market is witnessing notable dynamics within its Stage segmentation, which includes early, intermediate, and late age-related macular degeneration. Early age-related macular degeneration represents a critical phase where many individuals may display minimal symptoms, yet this stage holds immense significance as it lays the foundation for potential progression to more advanced stages. Awareness and early intervention strategies in this segment are vital to mitigate the risk of vision loss, as individuals in this phase can benefit from lifestyle modifications and monitoring.

As we move to the intermediate stage, patients often begin experiencing noticeable vision changes, making this segment crucial from a treatment standpoint. The intermediate AMD stage is characterized by the accumulation of drusen and retinal pigment changes that can lead to more significant vision impairment. Understanding the patient demographics and effective treatment options during this stage can leverage market growth opportunities, especially as the population ages.

The late age-related macular degeneration stage, often marked by severe vision loss and geographic atrophy, presents unique challenges and stresses the need for comprehensive care approaches. This segment accounts for a significant portion of the AMD burden and impacts patients' quality of life profoundly. The increased prevalence of late AMD correlates with the growing elderly population in the US, driving healthcare demands and indicating the importance of advanced therapeutic interventions to manage symptoms effectively.
Overall, the US Dry Age-Related Macular Degeneration (AMD) Market revenue will likely benefit from innovations across these stages, with insights derived from market growth enabling tailored therapies and preventive strategies to enhance patient outcomes.

This segmentation not only highlights the need for enhanced clinical care but also emphasizes the potential economic impact on healthcare systems. The structure of the US Dry Age-Related Macular Degeneration (AMD) Market segmentation supports a focused approach to the development and delivery of specialized solutions catering to each stage's unique requirements, thereby encouraging comprehensive understanding and research within the industry.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Dry Age-Related Macular Degeneration (AMD) Market Age Group Insights

The US Dry Age-Related Macular Degeneration (AMD) Market exhibits significant segmentation by age group, which plays a crucial role in shaping the market landscape. As the population ages, the prevalence of AMD increases notably among individuals above 60 years, where the majority of cases are reported. Specifically, the age group above 75 years is particularly vital, reflecting a pronounced susceptibility to vision impairment caused by AMD, making this demographic a key focus for treatment and intervention strategies. The increasing life expectancy in the US and rising awareness about eye health are driving factors in this market, leading to growing demand for AMD diagnostics and therapies.

Additionally, the above 40 years age group is becoming increasingly relevant as early signs of AMD can start manifesting, emphasizing the need for early detection and preventive measures. This age-specific segmentation allows stakeholders to tailor marketing and product development efforts effectively, addressing the unique needs of each group. Understanding these dynamics is essential for navigating the US Dry Age-Related Macular Degeneration (AMD) Market industry, as it presents both challenges and opportunities in delivering specialized care and advancing AMD management solutions.

Dry Age-Related Macular Degeneration (AMD) Market Diagnosis and Treatment Insights

The Diagnosis and Treatment segment of the US Dry Age-Related Macular Degeneration (AMD) Market has been experiencing notable advancements, reflecting the rising prevalence of AMD among the aging population in the U.S. Effective diagnosis techniques are critical as they enable timely intervention, with leading tools including optical coherence tomography and fundus photography playing a vital role in early detection. Meanwhile, the treatment landscape encompasses an array of approaches aimed at managing disease progression and alleviating symptoms, with a focus on nutritional supplements, anti-VEGF therapies, and emerging gene therapies gaining traction.

As the population ages, the demand for innovative treatments is expected to rise, driving industry growth. Moreover, the integration of technology in both diagnosis and treatment is reshaping care, offering improved patient outcomes. With a substantial portion of the elderly population at risk, the significance of this segment cannot be overstated, highlighting an urgent need for continuous evolution in strategies to combat AMD effectively in the U.S.

Dry Age-Related Macular Degeneration (AMD) Market Route of Administration Insights

The Route of Administration segment in the US Dry Age-Related Macular Degeneration (AMD) Market plays a pivotal role in the distribution of therapies aimed at managing this prevalent age-related condition. The importance of the Route of Administration stems from its direct impact on the efficacy and patient compliance associated with treatment regimens. Among the various methods, oral administration has gained traction due to its ease of use and patient-friendly nature, making it accessible to a broader demographic. In contrast, injectables are significant for their ability to deliver targeted therapy, often yielding faster results, particularly in cases requiring immediate intervention.

With the increasing prevalence of AMD in the aging US population, understanding the intricacies of these administration routes is crucial for the development of effective treatment options. As per the Centers for Disease Control and Prevention (CDC), more than 2 million Americans aged 50 and older are affected by AMD, highlighting the pressing need for innovative and efficacious routes of therapy that cater to patient preferences and clinical requirements. As the market evolves, the Route of Administration will likely adapt to technological advancements and changing patient needs, leading to growth opportunities in the segment.

Dry Age-Related Macular Degeneration (AMD) Market End Users Insights

The End Users segment of the US Dry Age-Related Macular Degeneration (AMD) Market plays a crucial role in the overall landscape of eye health services. Hospitals and clinics are at the forefront of diagnosis and treatment, offering specialized care that is essential for managing AMD. Diagnostic centers provide critical services that include advanced imaging and testing, enabling early detection of the disease and facilitating timely interventions. Academic and research institutes contribute significantly to the market through innovation and clinical trials, paving the way for new treatment options and technologies.

The increasing prevalence of AMD in the aging US population drives the demand within these areas, as they are pivotal in providing comprehensive care and educational support. Additionally, advancements in research and technology are enhancing the capabilities of healthcare providers, allowing them to offer more effective and personalized treatment solutions. As the market evolves, collaboration among these End Users will likely be essential in addressing the challenges posed by AMD, thereby improving patient outcomes and shaping future strategies within the market.

US Dry Age-Related Macular Degeneration (AMD) Market Key Players and Competitive Insights

The competitive landscape of the US Dry Age-Related Macular Degeneration (AMD) Market is characterized by dynamic growth and innovation driven by extensive research and development initiatives. This market focuses on the treatment and management of Dry AMD, an affliction primarily affecting the elderly population, with implications for vision health and overall quality of life. Various players in the industry are leveraging advanced technologies and conducting clinical trials to explore novel treatment modalities, thereby enhancing patient outcomes and redefining therapeutic options available for this degenerative eye condition. The competition is intense, with companies striving to capture market share through strategic partnerships, acquisitions, and the introduction of cutting-edge products that meet the evolving needs of healthcare providers and patients alike.

Kite Pharma has established a significant presence within the US Dry Age-Related Macular Degeneration (AMD) Market, primarily focusing on leveraging its expertise in cellular therapies for potential treatment interventions. One of the key strengths of Kite Pharma lies in its commitment to research and its innovative approach to developing therapies that target the underlying causes of AMD. This company possesses a robust pipeline of product candidates that are designed to address advanced stages of the disease. Additionally, Kite Pharma’s vigorous collaboration with academic institutions and research organizations enhances its capabilities in translating scientific discoveries into viable treatment options for patients suffering from Dry AMD. The organization's emphasis on patient-centric approaches and personalized medicine further solidifies its competitive position in this niche segment of the healthcare industry.

Genentech holds a prominent position in the US Dry Age-Related Macular Degeneration (AMD) Market by offering a variety of therapeutics that cater to patients dealing with this condition. The company is known for its strong portfolio of anti-VEGF agents, which have been instrumental in managing neovascular AMD and hold potential applications in the treatment of dry AMD as well. Genentech's significant investments in research and development have fostered a steady flow of innovative product solutions, solidifying its reputation as a leader in this segment. Along with its robust product offerings, Genentech has engaged in strategic mergers and acquisitions to enhance its research capabilities and broaden its market reach within the US. Its collaborations with healthcare providers and involvement in community outreach programs further strengthen its market presence, allowing Genentech to act as a critical player in advancing the treatment landscape for Dry AMD and ultimately improving patient outcomes through cutting-edge science and medical advances.

Key Companies in the US Dry Age-Related Macular Degeneration (AMD) Market Include

• Kite Pharma


• Genentech


• Oxurion


• Iveric bio


• Bristol-Myers Squibb


• Pfizer


• Novartis


• Santen Pharmaceutical


• Alimera Sciences


• Astellas Pharma


• Eyenovia


• Neurotez


• Regeneron Pharmaceuticals


• Apellis Pharmaceuticals

US Dry Age-Related Macular Degeneration (AMD) Market Industry Developments

Significant developments have occurred recently in the US Dry Age-Related Macular Degeneration (AMD) market. In July 2023, Apellis Pharmaceuticals announced the FDA approval of its innovative treatment, which has the potential to change the management approach for patients suffering from dry AMD. This approval marks a crucial milestone in the market, addressing an unmet need for effective treatment options. On the merger and acquisition front, in September 2023, Regeneron Pharmaceuticals acquired Iveric Bio, which is expected to bolster Regeneron's pipeline in AMD and optimize collaborative efforts to enhance patient outcomes.

Furthermore, Genentech continues to advance its research and development initiatives, focusing on novel therapies that target AMD in light of the growing patient population projected by the CDC, which estimates that by 2030, nearly 3 million Americans will be affected by AMD. The competitive landscape is further evolving, with increased investment from companies such as Novartis and Kite Pharma, reinforcing their commitment to developing groundbreaking therapies for AMD. The surge in market valuation and research funding reflects a promising trajectory for advancements in AMD care in the US.

Dry Age-Related Macular Degeneration (AMD) Market Segmentation Insights

• Dry Age-Related Macular Degeneration (AMD) Market Stage Outlook
  
  
  
  • Early Age-Related Macular Degeneration
  
  
  • Intermediate Age-Related Macular Degeneration
  
  
  • Late Age-Related Macular Degeneration
  
  
  
  

• Dry Age-Related Macular Degeneration (AMD) Market Age Group Outlook
  
  
  
  • Above 75 years
  
  
  • Above 60 years
  
  
  • Above 40 years
  
  
  
  

• Dry Age-Related Macular Degeneration (AMD) Market Diagnosis and Treatment Outlook
  
  
  
  • Treatment
  
  
  • Diagnosis
  
  
  
  

• Dry Age-Related Macular Degeneration (AMD) Market Route of Administration Outlook
  
  
  
  • Oral
  
  
  • Injectables
  
  
  
  

• 
  

  Dry Age-Related Macular Degeneration (AMD) Market End Users Outlook

  
  
  
  
  • 
    

    Hospitals Clinics

    
    
  
  
  • 
    

    Diagnostic Centers

    
    
  
  
  • 
    

    Academic Research Institutes

    
    
  
  
  
  

Report Attribute/Metric	Details
Market Size 2023	1.0 (USD Billion)
Market Size 2024	1.2 (USD Billion)
Market Size 2035	2.5 (USD Billion)
Compound Annual Growth Rate (CAGR)	6.9% (2025 - 2035)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Base Year	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Kite Pharma, Genentech, Oxurion, Iveric Bio, Bristol-Myers Squibb, Pfizer, Novartis, Santen Pharmaceutical, Alimera Sciences, Astellas Pharma, Eyenovia, Neurotez, Regeneron Pharmaceuticals, Apellis Pharmaceuticals
Segments Covered	Stage, Age Group, Diagnosis and Treatment, Route of Administration, End Users
Key Market Opportunities	Targeted gene therapies, Innovative nutritional supplements, Telemedicine for AMD management, Enhanced diagnostic technologies, Increasing geriatric population awareness
Key Market Dynamics	Rising elderly population, Increasing prevalence of AMD, Growing awareness and screening, Advancements in treatment options, High healthcare expenditure
Countries Covered	US